Patents by Inventor Jinming Gu
Jinming Gu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240010748Abstract: A bispecific antibody directed against Claudin 18.2 and CD3, pharmaceutical compositions including the bispecific antibody, and a use thereof in the treatment of cancer are provided. The bispecific antibody includes an anti-CLDN18.2 binding domain and an anti-CD3 binding domain, the first binding domain being capable of binding to a CLDN18.2 protein, the second binding domain being capable of binding to CD3.Type: ApplicationFiled: November 10, 2021Publication date: January 11, 2024Applicant: SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD.Inventors: Jiahua JIANG, Xiao LUO, Jinming GU, Chuan-Chu CHOU, Shihao CHEN, Yingying YANG
-
Patent number: 11680100Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.Type: GrantFiled: December 15, 2020Date of Patent: June 20, 2023Assignees: Hansoh (Shanghai) Healthtech Co., Ltd., Changzhou Hansoh Pharmaceutical Co., Ltd.Inventors: Jinming Gu, Xiaohua Wang, Xin Ye, Liuqing Yang, Ting Zhang, Weikang Tao, Lianshan Zhang
-
Patent number: 11359021Abstract: A novel PD-L1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. A humanized antibody comprising a CDR of the PD-L1 antibody, a pharmaceutical composition comprising the PD-L1 antibody and the antigen-binding fragment thereof and a use of the PD-L1 antibody as a drug. A use of a humanized PD-L1 antibody in preparing a drug for treating diseases or disorders associated with PD-L1.Type: GrantFiled: January 9, 2019Date of Patent: June 14, 2022Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.Inventors: Xiaoling Gu, Jiahua Jiang, Lei Zhang, Qiyue Hu, Jinming Gu, Weikang Tao
-
Patent number: 11274142Abstract: The present invention provides a fusion protein containing TGF-? receptor and pharmaceutical use thereof. Further, the present invention provides a bifunctional fusion protein comprising the PD-L1 antibody targeting portion and the TGF-?RII extracellular domain, and a pharmaceutical composition comprising the fusion protein containing TGF-? receptor, and the use thereof in the preparation of anti-cancer drug.Type: GrantFiled: May 11, 2018Date of Patent: March 15, 2022Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Jinming Gu, Xiao Luo, Weikang Tao
-
Publication number: 20210101984Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.Type: ApplicationFiled: December 15, 2020Publication date: April 8, 2021Inventors: Jinming GU, Xiaohua WANG, Xin YE, Liuqing YANG, Ting ZHANG, Weikang TAO, Lianshan ZHANG
-
Patent number: 10899837Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.Type: GrantFiled: March 30, 2018Date of Patent: January 26, 2021Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Jinming Gu, Xiaohua Wang, Xin Ye, Liuqing Yang, Ting Zhang, Weikang Tao, Lianshan Zhang
-
Publication number: 20200339692Abstract: A novel PD-L1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. A humanized antibody comprising a CDR of the PD-L1 antibody, a pharmaceutical composition comprising the PD-L1 antibody and the antigen-binding fragment thereof and a use of the PD-L1 antibody as a drug. A use of a humanized PD-L1 antibody in preparing a drug for treating diseases or disorders associated with PD-L1.Type: ApplicationFiled: January 9, 2019Publication date: October 29, 2020Applicants: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.Inventors: Xiaoling GU, Jiahua JIANG, Lei ZHANG, Qiyue HU, Jinming GU, Weikang TAO
-
Publication number: 20200157180Abstract: The present invention provides a fusion protein containing TGF-? receptor and pharmaceutical use thereof. Further, the present invention provides a bifunctional fusion protein comprising the PD-L1 antibody targeting portion and the TGF-?RII extracellular domain, and a pharmaceutical composition comprising the fusion protein containing TGF-? receptor, and the use thereof in the preparation of anti-cancer drug.Type: ApplicationFiled: May 11, 2018Publication date: May 21, 2020Inventors: Jinming GU, Xiao LUO, Weikang TAO
-
Publication number: 20200031934Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.Type: ApplicationFiled: March 30, 2018Publication date: January 30, 2020Inventors: Jinming GU, Xiaohua WANG, Xin YE, Liuqing YANG, Ting ZHANG, Weikang TAO, Lianshan ZHANG
-
Patent number: 8730230Abstract: The present invention provides an image/graphics data display mechanism for continuously displaying image/graphics data on multiple display devices of a computer that contains a system memory directly accessed by the computer's CPU during the CPU's power saving non-responding period, wherein there is provided sufficient system bandwidth, the mechanism of the present invention is independent on the resolution running on each display device and the number of display devices connected to the computer system. The mechanism provides two approaches to achieve continuous display of image/graphics data on multiple display devices computer system. In the first approach, a common clock source is used to coordinate display device horizontal synchronization signals, vertical synchronization signals, horizontal blank periods, and vertical blank periods. In the second approach, the mechanism has a control on the lengths and occurrences of the display device blank periods.Type: GrantFiled: August 12, 2003Date of Patent: May 20, 2014Assignee: VIA Technologies, Inc.Inventors: Yi-Fang Michael Shiuan, Xinwei Yang, Jinming Gu, Iming Pai
-
Patent number: 8681205Abstract: An interface unit is described that comprises a buffer for storing captured video data generated by a three dimensional (3D) device intended for a 3D monitor. The interface unit further comprises a synchronization signal extractor configured to extract vertical synchronization (vsync) signals from the video data and a control signal unit configured to derive control signals for a viewing device based on the stored vsync signals. The interface unit transmits the control signals to the viewing device.Type: GrantFiled: April 13, 2011Date of Patent: March 25, 2014Assignee: Via Technologies, Inc.Inventors: Iming Pai, Jinming Gu, Xinwei Yang
-
Publication number: 20110310223Abstract: An interface unit is described that comprises a buffer for storing captured video data generated by a three dimensional (3D) device intended for a 3D monitor. The interface unit further comprises a synchronization signal extractor configured to extract vertical synchronization (vsync) signals from the video data and a control signal unit configured to derive control signals for a viewing device based on the stored vsync signals. The interface unit transmits the control signals to the viewing device.Type: ApplicationFiled: April 13, 2011Publication date: December 22, 2011Applicant: VIA TECHNOLOGIES, INC.Inventors: Iming Pai, Jinming Gu, Xinwei Yang
-
Publication number: 20110275697Abstract: The present invention provides methods for modulating the level or activity of cyclin D by inhibiting EGLN2 expression or activity. The methods are particularly useful for treating or preventing a disorder associated with elevated cyclin D levels or activity, such as cancer.Type: ApplicationFiled: February 12, 2009Publication date: November 10, 2011Applicant: DANA FARBER CANCER INSTITUTE, INC.Inventors: William G. Kaelin, JR., Archana Bommi-Reddy, Jinming Gu
-
Patent number: 7897741Abstract: The present invention relates to polypeptide and nucleic acids constructs which are useful for determining the cell cycle status of a mammalian cell. Host cells transfected with these nucleic acid constructs can be used to determine the effects that test agents have upon the mammalian cell cycle.Type: GrantFiled: September 16, 2009Date of Patent: March 1, 2011Assignee: GE Healthcare UK LimitedInventors: Suzanne Hancock, Simon Stubbs, Nicholas Thomas, Ellen Fanning, Jinming Gu
-
Patent number: 7745123Abstract: The present invention relates to non-destructive and dynamic means for determining the cell cycle position of living cells. The invention provides stable cell lines which can be used to determine the cell cycle position, together with methods for measuring the effect of a test agent on the cell cycle position.Type: GrantFiled: July 22, 2005Date of Patent: June 29, 2010Assignees: GE Healthcare UK Limited, Vanderbilt UniversityInventors: Suzanne Hancock, Simon Stubbs, Nicholas Thomas, Ellen Fanning, Jinming Gu
-
Publication number: 20100028899Abstract: The present invention relates to polypeptide and nucleic acids constructs which are useful for determining the cell cycle status of a mammalian cell. Host cells transfected with these nucleic acid constructs can be used to determine the effects that test agents have upon the mammalian cell cycle.Type: ApplicationFiled: September 16, 2009Publication date: February 4, 2010Applicant: GE HEALTHCARE UK LIMITEDInventors: Suzanne Hancock, Simon Stubbs, Nicholas Thomas, Ellen Fanning, Jinming Gu
-
Patent number: 7612189Abstract: The present invention relates to polypeptide and nucleic acids constructs which are useful for determining the cell cycle status of a mammalian cell. Host cells transfected with these nucleic acid constructs can be used to determine the effects that test agents have upon the mammalian cell cycle.Type: GrantFiled: July 22, 2005Date of Patent: November 3, 2009Assignees: GE Healthcare UK Limited, Vanderbilt UniversityInventors: Suzanne Hancock, Simon Stubbs, Nicholas Thomas, Ellen Fanning, Jinming Gu
-
Publication number: 20070264681Abstract: The present invention relates to polypeptide and nucleic acids constructs which are useful for determining the cell cycle status of a mammalian cell. Host cells transfected with these nucleic acid constructs can be used to determine the effects that test agents have upon the mammalian cell cycle.Type: ApplicationFiled: July 22, 2005Publication date: November 15, 2007Applicants: GE HEALTHCARE UK LIMITED, VANDERBILT UNIVERSITYInventors: Suzanne Hancock, Simon Stubbs, Nicholas Thomas, Ellen Fanning, Jinming Gu
-
Publication number: 20070238144Abstract: The present invention relates to non-destructive and dynamic means for determining the cell cycle position of living cells. The invention provides stable cell lines which can be used to determine the cell cycle position, together with methods for measuring the effect of a test agent on the cell cycle position.Type: ApplicationFiled: July 22, 2005Publication date: October 11, 2007Applicants: GE HEALTHCARE UK LIMITED, VANDERBILT UNIVERSITYInventors: Suzanne Hancock, Simon Stubbs, Nicholas Thomas, Ellen Fanning, Jinming Gu
-
Publication number: 20070212707Abstract: The present invention relates to nucleic acid reporter constructs and host cells transfected with said constructs. The invention also relates to methods which are useful for determining the cell cycle status of a mammalian cell and for determining the effect of a test agent on the cell cycle position of a mammalian cell.Type: ApplicationFiled: July 22, 2005Publication date: September 13, 2007Applicants: GE HEALTHCARE UK LIMITED, VANDERBILT UNIVERSITYInventors: Suzanne Hancock, Simon Stubbs, Nicholas Thomas, Ellen Fanning, Jinming Gu